ARTICLE | Company News
Emergent BioSolutions Inc, U.S. Department of Health and Human Services infectious news
March 30, 2015 7:00 AM UTC
HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded Emergent a contract valued at $31 million to develop NuThrax ( AV7909) for post-exposure prophylaxis of anthrax disease. The contract will support process validation, consistency lot manufacture, assay validation, non-clinical studies and preparation for a Phase III trial. Last year, Emergent completed a Phase II trial of NuThrax for the indication. NuThrax is a third-generation anthrax vaccine consisting of BioThrax, an adsorbed anthrax vaccine, and CPG 7909, an immunostimulatory compound. ...